Pre-treatment blood parameters as an economical predictive marker for predicting treatment response in locally advanced cervical cancer [version 2; peer review: 2 approved]
Background Cervical cancer poses a significant public health challenge, particularly in low and middle-income countries. Despite advancements in treatment, the disease remains a leading cause of cancer-related deaths among women globally. Chemoradiation utilizing cisplatin has been the cornerstone t...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2025-04-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/14-118/v2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849700153959645184 |
|---|---|
| author | Paul Simon Johan Sunny Athiyamaan MS Vishnumaya N Pooja MS Dilson Lobo Challapalli Srinivas Fathima Shada Abhishek Krishna Sourjya Banerjee |
| author_facet | Paul Simon Johan Sunny Athiyamaan MS Vishnumaya N Pooja MS Dilson Lobo Challapalli Srinivas Fathima Shada Abhishek Krishna Sourjya Banerjee |
| author_sort | Paul Simon |
| collection | DOAJ |
| description | Background Cervical cancer poses a significant public health challenge, particularly in low and middle-income countries. Despite advancements in treatment, the disease remains a leading cause of cancer-related deaths among women globally. Chemoradiation utilizing cisplatin has been the cornerstone therapy for locally advanced cervical cancer. Prognostic biomarkers, including hematological parameters, have emerged as valuable tools in guiding treatment decisions and predicting outcomes. Methodology Data from patients treated between January 2021 and June 2022 were analyzed. Demographic information, histopathology, pre-treatment blood parameters, treatment details, and response assessments were collected. The parameters assessed included hemoglobin levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and eosinophil albumin ratio (EAR). Receiver operating characteristic (ROC) curve analysis was conducted to determine optimal cut-off values for these biomarkers. Results Of the 140 patients included, the majority had squamous cell carcinoma (92%) and were at stage II or III. Complete response to treatment was observed in 86.4% of patients. Non-responders demonstrated significantly higher levels of hemoglobin, NLR, and EAR, along with lower PNI levels compared to responders. ROC analysis revealed cut-off values for hemoglobin (< 9.5), NLR (< 2.98), PLR (> 289.26), PNI (< 37.67), and EAR (< 49.63) associated with treatment response. Conclusion The study highlights the potential utility of pre-treatment blood parameters as predictive markers for treatment response in locally advanced cervical cancer. Lower hemoglobin, higher NLR, and EAR, along with reduced PNI, were associated with poorer treatment outcomes. Integration of these biomarkers into clinical practice could aid in treatment planning and improve patient outcomes. Further validation and prospective studies are warranted to establish the role of these biomarkers in guiding personalized treatment strategies for cervical cancer patients. |
| format | Article |
| id | doaj-art-ec866bf37a8e49c1aa94d7060a884edf |
| institution | DOAJ |
| issn | 2046-1402 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj-art-ec866bf37a8e49c1aa94d7060a884edf2025-08-20T03:18:22ZengF1000 Research LtdF1000Research2046-14022025-04-011410.12688/f1000research.160308.2180510Pre-treatment blood parameters as an economical predictive marker for predicting treatment response in locally advanced cervical cancer [version 2; peer review: 2 approved]Paul Simon0Johan Sunny1Athiyamaan MS2https://orcid.org/0000-0003-4691-9728Vishnumaya N3Pooja MS4Dilson Lobo5https://orcid.org/0000-0002-9222-863XChallapalli Srinivas6Fathima Shada7Abhishek Krishna8https://orcid.org/0000-0002-9318-7024Sourjya Banerjee9Department of Radiation Oncology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Karnataka, Manipal, IndiaDepartment of Radiation Oncology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Karnataka, Manipal, IndiaDepartment of Radiation Oncology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Karnataka, Manipal, IndiaDepartment of Radiation Oncology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Karnataka, Manipal, IndiaDepartment of Radiation Oncology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Karnataka, Manipal, IndiaDepartment of Radiation Oncology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Karnataka, Manipal, IndiaDepartment of Radiation Oncology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Karnataka, Manipal, IndiaDepartment of Radiation Oncology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Karnataka, Manipal, IndiaDepartment of Radiation Oncology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Karnataka, Manipal, IndiaDepartment of Radiation Oncology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Karnataka, Manipal, IndiaBackground Cervical cancer poses a significant public health challenge, particularly in low and middle-income countries. Despite advancements in treatment, the disease remains a leading cause of cancer-related deaths among women globally. Chemoradiation utilizing cisplatin has been the cornerstone therapy for locally advanced cervical cancer. Prognostic biomarkers, including hematological parameters, have emerged as valuable tools in guiding treatment decisions and predicting outcomes. Methodology Data from patients treated between January 2021 and June 2022 were analyzed. Demographic information, histopathology, pre-treatment blood parameters, treatment details, and response assessments were collected. The parameters assessed included hemoglobin levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and eosinophil albumin ratio (EAR). Receiver operating characteristic (ROC) curve analysis was conducted to determine optimal cut-off values for these biomarkers. Results Of the 140 patients included, the majority had squamous cell carcinoma (92%) and were at stage II or III. Complete response to treatment was observed in 86.4% of patients. Non-responders demonstrated significantly higher levels of hemoglobin, NLR, and EAR, along with lower PNI levels compared to responders. ROC analysis revealed cut-off values for hemoglobin (< 9.5), NLR (< 2.98), PLR (> 289.26), PNI (< 37.67), and EAR (< 49.63) associated with treatment response. Conclusion The study highlights the potential utility of pre-treatment blood parameters as predictive markers for treatment response in locally advanced cervical cancer. Lower hemoglobin, higher NLR, and EAR, along with reduced PNI, were associated with poorer treatment outcomes. Integration of these biomarkers into clinical practice could aid in treatment planning and improve patient outcomes. Further validation and prospective studies are warranted to establish the role of these biomarkers in guiding personalized treatment strategies for cervical cancer patients.https://f1000research.com/articles/14-118/v2Keywords: Cervical cancer chemoradiation prognostic markers pre-treatment blood parameters treatment response.eng |
| spellingShingle | Paul Simon Johan Sunny Athiyamaan MS Vishnumaya N Pooja MS Dilson Lobo Challapalli Srinivas Fathima Shada Abhishek Krishna Sourjya Banerjee Pre-treatment blood parameters as an economical predictive marker for predicting treatment response in locally advanced cervical cancer [version 2; peer review: 2 approved] F1000Research Keywords: Cervical cancer chemoradiation prognostic markers pre-treatment blood parameters treatment response. eng |
| title | Pre-treatment blood parameters as an economical predictive marker for predicting treatment response in locally advanced cervical cancer [version 2; peer review: 2 approved] |
| title_full | Pre-treatment blood parameters as an economical predictive marker for predicting treatment response in locally advanced cervical cancer [version 2; peer review: 2 approved] |
| title_fullStr | Pre-treatment blood parameters as an economical predictive marker for predicting treatment response in locally advanced cervical cancer [version 2; peer review: 2 approved] |
| title_full_unstemmed | Pre-treatment blood parameters as an economical predictive marker for predicting treatment response in locally advanced cervical cancer [version 2; peer review: 2 approved] |
| title_short | Pre-treatment blood parameters as an economical predictive marker for predicting treatment response in locally advanced cervical cancer [version 2; peer review: 2 approved] |
| title_sort | pre treatment blood parameters as an economical predictive marker for predicting treatment response in locally advanced cervical cancer version 2 peer review 2 approved |
| topic | Keywords: Cervical cancer chemoradiation prognostic markers pre-treatment blood parameters treatment response. eng |
| url | https://f1000research.com/articles/14-118/v2 |
| work_keys_str_mv | AT paulsimon pretreatmentbloodparametersasaneconomicalpredictivemarkerforpredictingtreatmentresponseinlocallyadvancedcervicalcancerversion2peerreview2approved AT johansunny pretreatmentbloodparametersasaneconomicalpredictivemarkerforpredictingtreatmentresponseinlocallyadvancedcervicalcancerversion2peerreview2approved AT athiyamaanms pretreatmentbloodparametersasaneconomicalpredictivemarkerforpredictingtreatmentresponseinlocallyadvancedcervicalcancerversion2peerreview2approved AT vishnumayan pretreatmentbloodparametersasaneconomicalpredictivemarkerforpredictingtreatmentresponseinlocallyadvancedcervicalcancerversion2peerreview2approved AT poojams pretreatmentbloodparametersasaneconomicalpredictivemarkerforpredictingtreatmentresponseinlocallyadvancedcervicalcancerversion2peerreview2approved AT dilsonlobo pretreatmentbloodparametersasaneconomicalpredictivemarkerforpredictingtreatmentresponseinlocallyadvancedcervicalcancerversion2peerreview2approved AT challapallisrinivas pretreatmentbloodparametersasaneconomicalpredictivemarkerforpredictingtreatmentresponseinlocallyadvancedcervicalcancerversion2peerreview2approved AT fathimashada pretreatmentbloodparametersasaneconomicalpredictivemarkerforpredictingtreatmentresponseinlocallyadvancedcervicalcancerversion2peerreview2approved AT abhishekkrishna pretreatmentbloodparametersasaneconomicalpredictivemarkerforpredictingtreatmentresponseinlocallyadvancedcervicalcancerversion2peerreview2approved AT sourjyabanerjee pretreatmentbloodparametersasaneconomicalpredictivemarkerforpredictingtreatmentresponseinlocallyadvancedcervicalcancerversion2peerreview2approved |